Viracept

Known as: Agouron Brand of Nelfinavir Mesylate, Roche Brand of Nelfinavir Mesylate 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1995-2012
05101519952012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
This perspective first considers the potential impact of the Viracept-EMS case in the framework of the current understanding of… (More)
Is this relevant?
2009
2009
Prior to having performed in depth toxicological, genotoxicological and DMPK studies on ethyl methanesulfonate (EMS) providing… (More)
  • table 1
  • figure 1
Is this relevant?
2009
2009
Viracept (nelfinavir) is an HIV protease inhibitor supplied by Roche outside the US, Canada and Japan. Viracept was first… (More)
  • table 1
Is this relevant?
2008
2008
Ethyl methanesulfonate (EMS) is a potential human mutagenic and carcinogenic compound which has been found by Roche laboratories… (More)
Is this relevant?
2002
2002
Summary Forty (40) HIV positive patients with CD4 cell counts between 100 - 500 cellh/mm3 were recruited from 8 different centres… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
The 38th Interscience Conference on Antimicrobial Agents and Chemotherapy featured information on new antiretroviral treatments… (More)
Is this relevant?
1998
1998
  • AIDS treatment news
  • 1998
Agouron Pharmaceuticals is raising the price of its protease inhibitor Nelfinavir (Viracept) by 4.6 percent. The total cost… (More)
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Using a combination of iterative structure-based design and an analysis of oral pharmacokinetics and antiviral activity, AG1343… (More)
Is this relevant?
1997
1997
The Food and Drug Administration (FDA) approved nelfinavir (Viracept) for both adult and pediatric use for treatment of HIV… (More)
Is this relevant?
1997
1997
  • Brett Grodeck
  • Positively aware : the monthly journal of the…
  • 1997
The anticipated approval of the protease inhibitor nelfinavir (Viracept) will be good for those patients who cannot tolerate the… (More)
Is this relevant?